Welcome to our dedicated page for Vitrolife news (Ticker: VTRLY), a resource for investors and traders seeking the latest updates and insights on Vitrolife stock.
VITROLIFE AB (publ) is a leading global partner in reproductive health, focusing on better treatment outcomes for patients. The company is executing a new corporate strategy to drive sustainable growth through strategic pillars like innovation, investment in R&D, and expanding in key markets. With a strong commitment to operational excellence, VITROLIFE AB aims to enhance scalability, reduce costs, and maintain its position as a key player in the reproductive health industry.
Rhea-AI Summary
Vitrolife AB (publ) has acquired 100% of the shares in eFertility, a system and software company focused on transforming IVF clinic management. The acquisition is part of Vitrolife Group's strategy to standardize and digitalize IVF clinics globally. eFertility offers innovative solutions like eWitness and eBase, with revenues of EUR 1.5 million in 2023. The purchase price is EUR 9.6 million with a potential earn-out of EUR 8.4 million over three years. The acquisition is expected to close in mid-May 2024, financed by Vitrolife Group's cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Vitrolife AB held its Annual General Meeting, deciding on a SEK 1.00 per share dividend for 2023, re-election of board members, board remuneration details, auditor re-election, share issuance authorization, share-based incentive program, and more.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Vitrolife AB (publ) reported a first-quarter sales of SEK 841 million with flat growth in local currencies but a 2% decrease in SEK. Sales in APAC grew by 19%, while EMEA and Americas saw declines. Gross margin increased to 57.1%, EBITDA margin to 32.4%, and operating cash flow to SEK 198 million. Net income rose to SEK 115 million. The company restructured its business areas, with Genomics now part of Genetics. CEO Bronwyn Brophy O´Connor highlighted strong growth in APAC and solid margins.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Vitrolife AB (VTRLY) announces its Annual General Meeting for April 25, 2024, with key agenda items such as election of auditors and approval of financial reports. Shareholders must register by April 19, 2024, and can vote via postal or electronic means. The company proposes a dividend of SEK 1.00 per share and discusses the appointment of Board members, remuneration, and auditors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Vitrolife AB (publ) invites you to attend a conference call for the presentation of their Q1 2024 interim report. The call will be in English on April 18, 2024, at 10.00 a.m. CET. Registration required. The press release will be available at 8.00 CET on the same day. Recorded conference available for seven days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Vitrolife Group has released its Annual and Sustainability Report for 2023, available digitally in English and Swedish. The report follows the European Single Electronic Format (ESEF) and can be requested in print. Vitrolife AB (publ) complies with Swedish Securities Markets Act disclosure requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Vitrolife AB (VTRLY) announces Annual General Meeting with dividend proposal and board member re-election. Shareholders must register by April 19, 2024, and vote on various proposals including dividend payout, board composition, and auditor re-appointment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Vitrolife AB (publ) reported a 6% increase in fourth quarter sales to SEK 904 million, with sales in local currencies growing by 5%. Sales in APAC and EMEA increased by 16% and 6%, respectively, while sales in the Americas decreased by 5%. The company reported an impairment charge of SEK 4,300 million, resulting in a net income of SEK -4,179 million. Excluding the impairment charge, net income increased to SEK 121 million. Full-year sales increased by 9% to SEK 3,512 million, with a gross margin of 56.3%. The company proposed a dividend of SEK 135 million, excluding the non-cash impairment charge.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Vitrolife AB (VTRLY) invites to a conference call for the presentation of the fourth quarter and full year report 2023. The call will be held in English on February 2, 2024, at 10.00 a.m. CET. The press release for the full year report will be released at 8.00 CET on the same day. Participants include CEO Bronwyn Brophy O´Connor and CFO Patrik Tolf. The recorded version of the telephone conference will be available for seven days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Vitrolife AB (publ) (VITR.ST) is hosting a Capital Markets Day presentation in Stockholm, Sweden, to present its new corporate strategy focused on reproductive health. The company aims to achieve long-term, sustainable, profitable growth through innovation, expansion in key markets, and operational excellence. Vitrolife Group also plans to double its investment in R&D, increase capabilities in the US and China, and drive automation and digitalization across the business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of Vitrolife (VTRLY)?
The current stock price of Vitrolife (VTRLY) is $18 as of February 3, 2025.
What is the market cap of Vitrolife (VTRLY)?
The market cap of Vitrolife (VTRLY) is approximately 2.7B.
What is VITROLIFE AB (publ)'s focus?
The company focuses on better treatment outcomes for patients in the reproductive health sector.
What are VITROLIFE AB (publ)'s strategic pillars?
VITROLIFE AB (publ) is executing a new corporate strategy with pillars like innovation, R&D investment, and market expansion.
What is VITROLIFE AB (publ)'s commitment to innovation?
The company aims to lead in innovation by doubling investment in R&D to bring new high-impact solutions to the market.
How does VITROLIFE AB (publ) plan to expand in key markets?
The company plans to increase capabilities and footprint in key growth markets like the US and China while maintaining momentum in other regions.
What is VITROLIFE AB (publ)'s financial objective?
Dividend policy remains at 30% of net profit, with a focus on long-term sustainable growth.
What are some risks for VITROLIFE AB (publ)'s business?
Key risks include macro-economic risks, operational risks, and financial risks, as described in the Management report.
When will VITROLIFE AB (publ)'s Q4 and full-year 2023 financial report be presented?
The financial report will be presented on 2 February 2024.
Where can I access a live webcast of VITROLIFE AB (publ)'s Capital Markets Day presentation?
You can visit the company's official website to access the live webcast and accompanying materials.
Who are the key leaders of VITROLIFE AB (publ)?
The company is led by Bronwyn Brophy, CEO, and Patrik Tolf, CFO, along with members of the wider Vitrolife Group leadership team.
What is VITROLIFE AB (publ)'s mission?
VITROLIFE AB (publ) aims to be the leading global partner in reproductive health, striving for better treatment outcomes and improved patient care.
What are VITROLIFE AB (publ)'s long-term financial objectives?
The company aims to achieve long-term growth through strategic investments in automation, digitalization, and operational excellence.
What is VITROLIFE AB (publ)'s dividend policy?
Dividend policy remains at 30% of net profit, reflecting the company's focus on sustainable growth and shareholder value.
Vitrolife